他汀类药物在未破裂颅内动脉瘤患者显微手术或血管内治疗临床与影像学结局中的作用:系统综述与Meta分析
该系统综述与Meta分析检索PubMed/MEDLINE、Embase、Scopus和Web of Science至2024年8月1日,纳入8项研究5862例接受血管内动脉瘤治疗的患者。他汀使用与缺血性卒中风险增加相关(合并OR 1.51,95%CI 1.03-2.19,P=0.03),与出血并发症减少(合并OR 0.45,95%CI 0.24-0.85,P=0.01)及支架内狭窄减少(OR 2.31,95%CI 1.51-3.52,P=0.001)相关,完全闭塞率无差异。
要点
- 他汀使用与缺血性卒中风险增加相关(合并OR 1.51,95%CI 1.03-2.19,P=0.03)。
- 他汀使用与出血并发症减少相关(合并OR 0.45,95%CI 0.24-0.85,P=0.01)。
- 他汀使用与支架内狭窄减少相关(OR 2.31,95%CI 1.51-3.52,P=0.001),完全闭塞率无差异。
核心结论
- 他汀预处理可能降低血管内动脉瘤治疗后的出血并发症和支架内狭窄风险,但不改善血管造影闭塞。
- 发现缺血事件风险增加。
- 需要进一步数据验证这些发现并明确他汀在血管内治疗动脉瘤患者中的作用。
研究设计与样本
- 系统综述与Meta分析,检索PubMed/MEDLINE、Embase、Scopus和Web of Science数据库自建库至2024年8月1日。
- 纳入8项研究,共5862例患者,比较接受血管内动脉瘤治疗的他汀使用者与非使用者结局。
主要发现
- 血管内动脉瘤治疗后完全闭塞率在他汀使用者与非使用者间相似(合并OR 0.93,95%CI 0.70-1.23)。
- 他汀使用与缺血性卒中风险显著增加相关(合并OR 1.51,95%CI 1.03-2.19,P=0.03)。
- 神经性死亡(合并OR 0.74,95%CI 0.21-2.57,P=0.63)、全因死亡(合并OR 0.68,95%CI 0.16-2.90,P=0.61)或再治疗率(合并OR 0.76,95%CI 0.35-1.66,P=0.49)无差异。
- 他汀治疗与出血并发症减少相关(合并OR 0.45,95%CI 0.24-0.85,P=0.01)。
- 他汀使用不影响血栓风险(合并OR 1.28,95%CI 0.68-2.40,P=0.45),并减少支架内狭窄(OR 2.31,95%CI 1.51-3.52,P=0.001)。
局限性
- 需要进一步数据验证这些发现并明确他汀在血管内治疗动脉瘤患者中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of statin pretreatment on outcomes for patients undergoing endovascular treatment of intracranial aneurysms remains uncertain. We aimed to conduct a systematic review and meta-analysis evaluating the efficacy and safety of statins in this population. METHODS: We searched the PubMed/MEDLINE, Embase, Scopus, and Web of Science databases from inception to August 1, 2024. This study compares the outcomes between statin users and nonusers undergoing endovascular aneurysm treatment. RESULTS: Eight studies with 5862 patients were included. Complete occlusion rates after endovascular aneurysm treatment were similar between statin users and nonusers (pooled odds ratio [OR], 0.93; 95% confidence interval [CI], 0.70-1.23). Statin use was associated with a significantly increased risk of ischemic stroke (pooled OR, 1.51; 95% CI, 1.03-2.19, P = 0.03). No differences were seen in neurologic mortality (pooled OR, 0.74; 95% CI, 0.21-2.57; P = 0.63), all-cause mortality (pooled OR, 0.68; 95% CI, 0.16-2.90, P = 0.61), or retreatment rates (pooled OR, 0.76; 95% CI, 0.35-1.66; P = 0.49). Statin therapy was associated with decreased hemorrhagic complication (pooled OR, 0.45; 95% CI, 0.24-0.85; P = 0.01) but did not affect thrombosis risk (pooled OR, 1.28; 95% CI, 0.68-2.40; P = 0.45) and statin use decreased in-stent stenosis (OR, 2.31, 95% CI, 1.51-3.52; P = 0.001). CONCLUSIONS: Statin pretreatment may decrease the risk of hemorrhagic complications and in-stent stenosis after endovascular aneurysm therapy but does not improve angiographic occlusion. An increased hazard of ischemic events was found. Further data are needed to validate these findings and clarify the role of statins in patients with aneurysms undergoing endovascular procedures.
引用
- Habibi MA, Naseri Alavi SA, Mirjnani MS, et al. Role of Statins in the Clinical and Radiologic Outcomes of Patients with Unruptured Intracranial Aneurysm Undergoing Microsurgery or Endovascular Treatment: A Systematic Review and Meta-Analysis. World Neurosurg. 2024. PMID: 39603459. doi:10.1016/j.wneu.2024.11.080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。